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Abstract We develop a mathematical model of platelet, megakaryocyte, and thrombopoietin dynamics in
humans. We show that there is a single stationary solution that can undergo a Hopf bifurcation, and use
this information to investigate both normal and pathological platelet production, specifically cyclic throm-
bocytopenia. Carefully estimating model parameters from laboratory and clinical data, we then argue that a
subset of parameters are involved in the genesis of cyclic thrombocytopenia based on clinical information.
We provide model fits to the existing data for both platelet counts and thrombopoietin levels by changing
four parameters that have physiological correlates. Our results indicate that the primary change in cyclic
thrombocytopenia is an interference with, or destruction of, the thrombopoietin receptor with secondary
changes in other processes, including immune-mediated destruction of platelets and megakaryocyte defi-
ciency and failure in platelet production. This study contributes to the understanding of the origin of cyclic
thrombocytopenia as well as extending the modeling of thrombopoiesis.
Keywords Platelet regulation dynamics · thrombopoiesis · megakaryopoiesis · cyclic thrombocytopenia ·
dynamic diseases · delay differential equations
1 Introduction
Mammalian blood contains three major types of cells that are essential in the maintenance of life: the red
blood cells whose intracellular hemoglobin carries oxygen to tissues, the white blood cells responsible for
all immune responses, and the platelets which maintain the integrity of clotting mechanisms. This tricellular
system is known as the hematopoietic system.
The maintenance of hematological integrity in humans, as in all other mammals, is essential for normal
physiological function, and under most circumstances is wonderfully maintained by several intricate con-
trol mechanisms that are only partially understood. This control usually regulates the circulating levels of
leukocytes (white blood cells), erythrocytes (red blood cells), and thrombocytes (platelets) within relatively
narrow limits for a given individual notwithstanding the relatively wide variation within populations. For
example, human platelet levels remain relatively stable in the range 150 − 450 × 109 platelets/L with an
average of about 290× 109 platelets/L of blood [24].
The hematopoietic cells are estimated to constitute 90% of all cells in a human [64], and the lifetime pro-
duction of these cells in humans is rather surprising as the average human produces the equivalent of their
body weight in hematopoietic cells every decade of life [45]. Perhaps the most astonishing thing about this
enormous production is that it usually proceeds without a flaw.
Disturbances to this tightly controlled regulation, however, can be quite harmful and often manifests itself
as dynamic pathologies. Among these are a spectrum of periodic hematological diseases documented in the
clinical literature that have provided rich fodder for those interested in mathematically modeling the regu-
lation of hematopoiesis [23]. Many of these periodic hematological diseases appear to be what are known
as dynamic diseases [25]. Perhaps one of the best known and most studied of these periodic hematological
diseases is cyclic neutropenia [30], a condition where the neutrophils, erythrocyte precursors, and platelets
all oscillate at the same period in a given patient. A great deal is known about the pathogenesis of cyclic
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neutropenia [14], and it is now generally believed that the disorder is linked to an abnormally high level
of apoptosis in neutrophil precursors. This, in turn, leads to an elevated efflux of hematopoietic stem cells
into the neutrophil lineage causing a destabilization of stem cell dynamics and an ensuing oscillation that is
propagated into all of the hematopoietic lines.
Though the control of neutrophil production as well as the regulation of erythropoiesis have been the subject
of a number of modeling studies, there have been fewer treating the regulation of platelet production. One
of the earliest was that of Wichmann et al [73], which was followed by an exposition of their complete
hematopoiesis model [74]. Scholz et al [62] used the same modeling framework to try to understand the
response to chemotherapy. Motivated by observed oscillations in the platelet counts of healthy humans, von
Schulthess and Gessner [63] devised a conceptually different model for thrombopoiesis, which was followed
by Bélair and Mackey [3]. Building on this, Santillan et al [61] and Apostu and Mackey [1] further refined
the model to understand the origins of cyclic thrombocytopenia (CT).
In this work, we use recent laboratory and clinical data to develop a more physiologically realistic model for
the regulation of mammalian platelet production concentrating on humans, which takes into account both the
megakaryocytes and platelets and the effects of thrombopoietin on their dynamics. Sect. 2 first reviews the
relevant physiology of normal thrombogenesis and then briefly discusses cyclic thrombocytopenia. Next, in
Sect. 3 we derive the model for the dynamics of megakaryocytes, platelets, and thrombopoietin in humans.
We present in Sect. 4 several mathematical results that were derived for the model, including the existence
of a unique positive equilibrium, the linearization and stability analysis of the model equations about the
equilibrium, and a parameter sensitivity analysis for the model. In Sect. 5, we use data on cyclic thrombocy-
topenia patients as a benchmark against which to test the model. Starting with the parameters for a healthy
subject, we change these parameters to those for a CT patient, showing a parameter set where a Hopf bi-
furcation occurs. We conclude with a brief discussion of our results and comparison with previous work in
Sect. 6.
We have relegated more technical details to a series of appendices. Appendix A describes our estimation
of model parameters, Appendix B contains a proof of the existence and uniqueness of the steady state
solution of the model equations, while Appendix C contains a linearization of the full nonlinear model and a
derivation of the characteristic equation for the stability analysis of the linearized model. Appendix D gives
the full results of our study of the sensitivity to parameter changes of the model when all parameters are
held at the levels estimated for a healthy individual. Appendix E continues the stability analysis of three CT
patients from Sect. 5.4. Appendix F details the numerical techniques that we have used to fit the model to the
cyclic thrombocytopenia data that we have available, while Appendix G gives the details of the numerical
code we have used to solve the model equations.
2 Physiological background
2.1 Normal thrombopoiesis
Platelets are the hematological cells responsible for clotting and do so by adhering to the sites of damaged
tissue to produce a hemostatic plug, which forms the surface on which coagulation factors are activated for
clot formation. The mean platelet volume follows a log-normal distribution with respect to platelet count,
with an average mean platelet volume of 8.6 fL for an average platelet count of 290×109 platelets/L of blood
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[56, 24]. About one-third of the total mass of platelets is sequestered in an exchangeable splenic pool [2].
Platelets have a life span of about 8 to 10 days, which is determined by an internal apoptotic regulating
pathway, and are destroyed by the reticuloendothelial system [51].
Platelets are derived from megakaryocytes, large polyploid cells found in the bone marrow. Megakaryocytes
in turn are produced by the hematopoietic stem cells, also found in the bone marrow, which are responsible
for generating all blood cells in the body. Among others, hematopoietic stem cells give rise to early bi-lineage
progenitors that eventually undergo erythrocyte (red blood cell) or megakaryocyte differentiation. The differ-
entiation process eventually produces the colony-forming unit-megakaryocyte (CFU-Meg), a precursor cell
committed to megakaryocyte differentiation. These cells undergo mitosis (cell division) [55], which stops
some time after the CFU-Meg matures into a megakaryoblast, an early maturation stage of megakaryocytes.
After cell division ceases, megakaryocytes begin endomitosis – a process in which DNA replicates through
nuclear division without cell division while the cytoplasm remains intact [37]. DNA can replicate 2 to 7 times
during endomitosis, resulting in cells with DNA content between 8 and 128 times the normal diploid content
of DNA in a single, highly lobated nucleus. Megakaryocytes are generally classified by their ploidy, which
is the number of chromosomes that they have. A megakaryocyte ploidy of 2N refers to a megakaryocyte
that has not undergone endomitosis. The modal megakaryocyte ploidy in humans is 16N [33, 43], which
corresponds to a megakaryocyte with 8 times the normal diploid content of DNA. In general the higher the
ploidy number, the larger the megakaryocyte, with the diameter of megakaryocytes ranging from 20 to 60
µm depending on the ploidy [68].
As DNA replicates, the cytoplasm of the megakaryocyte expands and develops a demarcation membrane
that eventually becomes the external membrane of each platelet. Megakaryocytes are released from the bone
marrow and travel to the lungs, where the megakaryocytes shed platelets [34, 58, 69]. On average, one
megakaryocyte sheds between 1000 and 3000 platelets [29]. It is estimated that it takes 5 to 7 days for a
megakaryocyte to begin endomitosis, grow into a mature megakaryocyte, and shed platelets [37].
The principal hormone that regulates megakaryocyte and platelet development is thrombopoietin (TPO).
TPO is produced principally by the liver, and to a smaller extent, in the kidney and bone marrow [57, 59].
Its crystal structure is that of an anti-parallel four-helix bundle fold with two different binding sites for the
TPO receptor [21]. It is released into blood as a 95 kDa glycoprotein [41], and acts as the ligand for the
c-Mpl receptor, present on the surface of CFU-Meg, megakaryocytes, and platelets [19, 44]. On binding to
thrombopoietin, the receptor dimerizes and initiates a number of signal transduction events that eventually
stimulate differentiation and mitosis of CFU-Meg, increase the rate of endomitosis of megakaryocytes, and
reduce the rate of apoptosis of CFU-Meg and megakaryocytes [35, 48, 77]. The thrombopoietin is then
internalized, degraded, and removed from circulation. This internalization process is the major mechanism
of TPO removal from the blood by platelets and megakaryocytes [44].
Although TPO supports the survival of CFU-Meg and megakaryocytes, it is not essential. Elimination of the
thrombopoietin gene or its receptor in mice reduces megakaryocyte and platelet levels to approximately 10%
of normal [18]. The residual platelets and megakaryocytes are normal and functional, and the other blood
cells are also at their normal levels. The same observation has also been made in humans (Kaushansky,
private communication).
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2.2 Cyclical thrombocytopenia
Cyclic thrombocytopenia is a hematological disorder that causes the platelet count of an affected individual
to undergo large periodic fluctuations over time. In these individuals, platelet counts oscillate from very low
(1 × 109 platelets/L) to normal or very high levels (2000× 109 platelets/L) [66]. At the nadir, patients are
at risk of bruising and excessive bleeding, whereas at very high levels there is an increased risk of clot for-
mation. Little is known about the pathogenesis of the disease, which has been reviewed in [1, 10, 26, 66]. It
is well established that in premenopausal women with CT there is often a relation between blood hormonal
and platelet levels, but it is unclear whether this is causal. In other cases, clinical findings suggest at least
three possible origins: immune-mediated platelet destruction (autoimmune CT), megakaryocyte deficiency
and cyclic failure in platelet production (amegakaryocytic CT), and possible immune interference with or
destruction of the TPO receptor [26]. Autoimmune CT is thought to be an unusual form of immune throm-
bocytopenia purpura (a disease in which the platelet count is abnormally low). The hematological profile of
most affected patients reveals high levels of antiplatelet antibodies, shorter platelet lifespans at the platelet
nadir, and normal to high levels of marrow megakaryocytes. Amegakaryocytic CT is postulated to be a vari-
ant of acquired amegakaryocytic thrombocytopenic purpura and is mainly characterized by the absence of
megakaryocytes in the thrombocytopenia phase and increased megakaryocyte number during thrombocyto-
sis.
A curious feature of the disease is that the fluctuations appear only to be present in the platelet cell line and
not in the white or red blood cell lines. Swinburne and Mackey [66] and Apostu and Mackey [1] searched the
English literature and found and analyzed well-documented cases of cyclic thrombocytopenia. In no case was
there a report of fluctuations in the red or white blood cells. In other existing cyclic hematological disorders
like periodic chronic myelogenous leukemia [11], fluctuations appear in all major blood cell lines and are
all at the same period in a given subject. These diseases are believed to evolve from the hematopoietic stem
cell compartment in the bone marrow. In cyclic thrombocytopenia, fluctuations are observed in the platelet
line only, and therefore a destabilization of a peripheral control mechanism could play an important role
in the genesis of the disorder. This hypothesis was the starting point of the investigation and mathematical
modeling of Santillan et al [61] and Apostu and Mackey [1].
3 Mathematical model of thrombopoiesis
In this section, we develop our mathematical model for the regulation of megakaryocyte, platelet and throm-
bopoietin dynamics in humans. We describe the dynamics of the megakaryocytes as an age-structured model
(Sect. 3.1), which is divided in two stages: mitosis (Sect. 3.1.1) and endomitosis (Sect. 3.1.2). Platelet
(Sect. 3.2) and thrombopoietin (Sect. 3.3) dynamics are dealt with last. In the discussion of the develop-
ment of the model, the reader may find Fig. 1 helpful.
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Fig. 1 A schematic view of the model of human thrombopoiesis. Solid lines denote fluxes, dashed lines
terminating in solid circles denote positive feedback, and dashed lines ending with perpendicular lines denote
negative feedback. Hematopoietic stem cells enter the megakaryocyte lineage as well as the other blood
lines, undergo cell division, or are removed from the HSC pool through death. HSCs differentiated into
the megakaryocyte lineage undergo cell divisions for τm days, after which they stop dividing and start
endomitosis (nuclear division). These megakaryocytes undergo endomitosis for τe days until they finally
start to shed platelets. Platelets remain in circulation until they are removed at random by degradation or
cleared by macrophages due to senescence, a platelet-dependent mechanism. Thrombopoietin is produced
constitutively at a rate Tprod, and is removed from circulation either at random by degradation or by binding
to receptors present on platelets and megakaryocytes
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3.1 Megakaryocyte compartment
3.1.1 Mitosis
We first model the megakaryocyte mitosis phase, starting from the moment the hematopoietic stem cells
differentiate into the megakaryocytic lineage. These early cells, known as megakaryoblasts (or CFU-Meg in
tissue culture), undergo mitosis (cell division) for some time until they stop and begin endomitosis.
Letmm(t, a) be the cell density of megakaryoblasts as a function of time t and age a, andQ∗ the equilibrium
concentration of hematopoietic stem cells at time (we assume here that the quiescent stem cells are at their
normal steady state level throughout this paper). We further assume that stem cells enter the megakaryoblasts
compartment at a rate κP , and that a megakaryoblast proliferates for τm days at a thrombopoietin-dependent
(T (t)) rate of ηm(T (t)). As discussed in Sect. 2, while TPO stimulates mitosis of megakaryoblasts, it is not
necessary. Therefore, we assume a basal proliferation rate of megakaryoblasts even in absence of throm-
bopoietin. Based on these assumptions, we model the proliferation rate ηm(T (t)) as a Hill function
ηm(T ) = η
min
m + (η
max
m − η
min
m )
T
bm + T
, (1)
where the parameter ηminm is the minimum effective rate of proliferation in absence of thrombopoietin, ηmaxm
is the maximum effective rate of proliferation, and bm is the concentration of thrombopoietin at which the
proliferation is half maximal.
Three comments are in order. First, since we are not trying to model the details of megakaryoblast prolif-
eration and apoptosis dynamics, equation (1) simply gives an effective proliferation rate that includes both
cellular birth and death. Second, the choice of the Hill function in (1) is taken to reflect the fact that TPO
has a stimulatory, yet saturating, effect on the process. Third, in the absence of further experimental data,
the choice of Hill coefficient is unclear and we have therefore opted for an estimate consistent with the
qualitative observations by taking a Hill coefficient of 1.
The dynamics of megakaryoblasts, then, is modeled by means a time-age evolution equation given by
∂mm
∂t
+
∂mm
∂a
= ηm(T )mm, t > 0, a ∈ [0, τm] . (2)
For the boundary condition, we take mm(t, 0) = κPQ∗, which is the rate hematopoietic stem cells enter the
megakaryocyte lineage.
We solve Eq. (2) using the method of characteristics to obtain
mm(t, a) = κPQ
∗ exp
[ˆ t
t−a
ηm(T (s)) ds
]
, t > a, a ∈ [0, τm], (3)
and
mm(t, a) = mm(0, a− t) exp
[ˆ t
0
ηm(T (s)) ds
]
, t ∈ [0, a), a ∈ [0, τm]. (4)
It is convenient to define an initial function T (t) for t ∈ [−τm − τe, 0] and following (3) let
mm(0, a) = κPQ
∗ exp
[ˆ 0
−a
ηm(T (s)) ds
]
, a ∈ (0, τm)
so that equation (4) reduces to (3), and thus equation (3) can be applied for all t > 0.
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3.1.2 Endomitosis
Next we consider the endomitosis (endoreplication) phase, starting from the moment megakaryocytes begin
endomitosis until they start to shed platelets. During this period, megakaryocytes no longer multiply, but
rather grow in ploidy and size. Accordingly, we model the volume growth of megakaryocytes during en-
domitosis and we assume that megakaryocyte volume is an increasing function of megakaryocyte age so the
two may be simply related.
Let me(t, a) be the volume density of megakaryocytes in the endomitosis phase as a function of time t and
age a, Vm the volume of a single megakaryocyte of ploidy 2N at age a = 0. Suppose that a megakaryocyte
undergoes endomitosis for τe days and at a thrombopoietin-dependent rate of ηe(T (t)). As in the process of
mitosis, TPO stimulates endomitosis in megakaryocytes but is not strictly essential. Thus we assume a basal
endoreplication rate of megakaryocytes even in absence of thrombopoietin. Based on this fact, we model the
proliferation rate ηe(T (t)) as a Hill function
ηe(T ) = η
min
e + (η
max
e − η
min
e )
T
be + T
, (5)
where the parameter ηmine is the minimum effective rate of endomitosis in absence of thrombopoietin, ηmaxe
is the maximum effective rate of endomitosis, and be is the concentration of thrombopoietin at which the
endomitosis rate is half maximal. The comments relating to the choice of Hill function and coefficient
following (1) also apply here.
We model the volume growth of megakaryocytes, then, by means of a time-age structured equation given by
∂me
∂t
+
∂me
∂a
= ηe(T )me, t > 0, a ∈ [0, τe] . (6)
For the boundary condition, we take
me(t, 0) = Vmmm(t, τm) = VmκPQ
∗ exp
[ˆ t
t−τm
ηm(T (s)) ds
]
,
which is the product of the average volume of a megakaryocyte commencing endomitosis and the number
of megakaryocytes at the end of the mitotic phase.
As before we solve (6) using the method of characteristics and the initial function T (t) for t ∈ [−τm− τe, 0]
to obtain
me(t, a) = VmκPQ
∗ exp
[ˆ t−a
t−a−τm
ηm(T (s)) ds
]
exp
[ˆ t
t−a
ηe(T (s)) ds
]
, t > 0, a ∈ [0, τe]. (7)
The total megakaryocyte volume at time t is
Me (t) =
ˆ τe
0
me (t, a) da. (8)
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3.2 Platelet compartment
Platelet population dynamics are governed by the balance between platelet production and destruction. The
platelet population is comprised of both platelets in circulation as well as those sequestered primarily in
the spleen after their creation from megakaryocytes at the end of the endomitosis stage. Platelets die at a
random rate γP proportional to platelet numbers. Platelets are also removed by senescence and cleared by
macrophages [27] via a saturable mechanism, which we model via a saturable Hill function
αP
(P )nP
(bP )nP + (P )nP
,
where αP is the maximal platelet-dependent removal rate, bP is the platelet concentration at which the
removal rate is half its maximum and nP is the Hill coefficient modeling how steeply the platelet removal
rate changes with platelet levels. We assume senescence will be reduced when platelet concentrations are
low (the average age of platelets can be expected to be lower, since newly created platelets have age 0, and
there are few old platelets if the concentration is low), which implies nP > 1, and we choose nP = 2. Based
on these considerations, we model the dynamics of platelets via the differential equation
dP
dt
=
D0
βP
me(t, τe)− γPP − αP
(P )nP
(bP )nP + (P )nP
, (9)
where D0 is the fraction of megakaryocyte volume shed into platelets, and βP is the average volume of a
platelet.
3.3 Thrombopoietin compartment
Finally, as with platelets, we model TPO dynamics as the balance between production and destruction.
We assume that TPO is produced at a constant rate Tprod [42]. As thrombopoietin is cleared mainly by
receptors on megakaryocytes and circulating platelets, its endogenous removal rate is proportional to the
total volume of megakaryocytes and circulating platelets. Since only a finite number of TPO receptors can
clear thrombopoietin, we assume the endogenous removal rate is proportional to the saturable Hill function
(T )nT
(kT )nT + (T )nT
,
where kT is the thrombopoietin concentration at which the removal rate is half the maximum removal rate
and nT is the Hill coefficient modeling how steeply the TPO removal rate changes with TPO levels. Here, the
Hill coefficient nT will be determined by the stoichiometry of TPO receptor interactions. We also assume a
small renal clearance rate of γT proportional to TPO levels. Thus, we model the dynamics of thrombopoietin
with
dT
dt
= Tprod − γTT − αT (Me(t) + kSβPP )
(T )nT
(kT )nT + (T )nT
, (10)
where αT is the maximum removal rate of thrombopoietin by internalization and kS is the average fraction
of platelets circulating in the blood.
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3.4 Model summary
As detailed above, our model of thrombopoiesis consists of two integro-differential equations with constant
delays and an integral equation. The two differential equations model the dynamics of platelets and TPO,
while the integral equation models the volume of megakaryocytes in the bone marrow. Thus, to summarize,
our full model is given by
dP
dt
=
D0
βP
me(t, τe)− γPP − αP
(P )nP
(bP )nP + (P )nP
, (11)
dT
dt
= Tprod − γTT − αT (Me(t) + kSβPP )
(T )nT
(kT )nT + (T )nT
, (12)
where
me(t, a) = VmκPQ
∗ exp
[ˆ t−a
t−a−τm
ηm(T (s)) ds
]
exp
[ˆ t
t−a
ηe(T (s)) ds
]
(13)
and
Me(t) =
ˆ τe
0
me(t, a)da. (14)
The functions ηm(T ) and ηe(T ) are given by
ηm(T ) = η
min
m + (η
max
m − η
min
m )
T
bm + T
(15)
and
ηe(T ) = η
min
e + (η
max
e − η
min
e )
T
be + T
. (16)
All parameters are estimated in Appendix A, and the results of that estimation for a healthy human are
given in Table 1. We show the existence and uniqueness of a positive stationary solution to our model in
Appendix B. Of particular note, owing to the lack of data specific to the HSC dynamics, to avoid issues of
parameter identifiability Q(t) = Q∗ throughout.
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Name Interpretation Value Units References
Q∗ HSCs density 1.1 106 cells/kg [7]
κp HSC differentiation rate into megakaryocyte line 0.0072419 day-1 [7, 45]
Vm Volume of megakaryocyte of ploidy 2N 4pi(21)
3
24
fL [53]
τm MB proliferation duration 8.09 days Fit
ηminm Min MB proliferation rate 0.38874 day-1 Eq. (42)
ηmaxm Max MB proliferation rate 2.6828 day-1 Eq. (43)
bm TPO concentration for half max MB proliferation 706 pg / ml Fit
τe Endomitosis duration 5.0 days [22, 42]
ηmine Min endomitosis rate 0.41022 day-1 Eq. (44)
ηmaxe Max endomitosis rate 0.69335 day-1 Eq. (45)
be TPO concentration for half max endomitosis 92.1 pg / ml Fit
P ∗ Normal platelet level 31.071 109 platelets / kg [24]
βP Average volume of a platelet 8.6 fL [24]
D0 Fraction megakaryocytes shedding platelets 0.21829 — Eq. (41)
τP Mean platelet survival time 8.4 days [70]
αP Max platelet removal rate 212.95 109 platelets / kg / day Eq. (38), [70]
γP Random loss rate of platelets 0.05 day-1 Fit
bP Platelet levels for half max removal 308 109 platelets / kg Fit
nP Hill coefficient for platelet removal 2.0 — [32]
T ∗ TPO levels 100 pg / ml [42]
Tprod TPO production rate 61.6 pg / ml / day Fit
γT TPO renal clearance rate 0.01 day-1 Fit
kS Fraction of platelets circulating in the blood 2/3 — [2]
αT Maximum clearance rate of thrombopoietin 144.87 10−9pg kg / (fL ml day) Eq. (46)
kT TPO half max clearance 3180 pg / ml Fit
nT TPO clearance Hill coefficient 2.0 — [32]
Table 1 Summary of units and values of all model parameters. HSC denotes hematopoietic stem cell, MB denotes megakaryoblast. All
units have up to 5 significant digits
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4 Model Analysis
The model presented in Eqs. (11)–(16) is a nonlinear system of two integro-differential equations that de-
scribes the process of thrombopoiesis. This section examines some of the mathematical results which can
be derived from the model. We establish the existence of a unique positive equilibrium in Appendix B. A
local linear analysis about this equilibrium provides a complicated characteristic equation, which is studied
numerically for stability and gives information on the parameter sensitivity for the model. This local analysis
provides the basis for examining Hopf bifurcations.
The model from Sect. 3.4 is condensed to two differential equations depending only on P and T . The model
equation for the platelets has the form
dP
dt
=
D0VmκPQ
∗
βP
exp
[ˆ t−τe
t−τe−τm
ηm(T (s))ds
]
exp
[ˆ t
t−τe
ηe(T (s)) ds
]
− γPP − F (P ), (17)
where
F (P ) = αP
(P )nP
(bP )nP + (P )nP
.
The model equation for the thrombopoietin is
dT
dt
= Tprod − γTT − αT
(ˆ τe
0
VmκPQ
∗ exp
[ˆ t−a
t−a−τm
ηm(T (s)) ds
]
× exp
[ˆ t
t−a
ηe(T (s)) ds
]
da+ kSβPP
)
G(T ),
(18)
where
G(T ) =
(T )nT
(kT )nT + (T )nT
.
4.1 Linearization about the single steady state
The study of a steady state solution begins by setting (17) and (18) equal to zero to determine the equilibrium
solution (P ∗, T ∗). The steady state solution of (18) readily gives P ∗ depending on T ∗ and is shown to be a
function monotonically decreasing in T ∗ from +∞ to negative values for T ∗ > 0. This information is used
in Eq. (17), where the decay terms are set equal to the production term. The monotonicity of the decay terms
(decreasing in T ∗) combined with the positively bounded monotonicity of the production terms (increasing
in T ∗) result in the existence of a unique positive equilibrium, (P ∗, T ∗). Details of the proof are presented
in Appendix B.
The next step in the local analysis is linearizing Eqs. (17) and (18) about the unique equilibrium (P ∗, T ∗).
See Appendix C for the details of this process. Let x(t) = P (t) − P ∗ and y(t) = T (t) − T ∗, and denote
by ∂P and ∂T the partial derivatives with respect to the platelet and TPO variables, respectively. Linearizing
Eq. (17) about the equilibrium yields
dx
dt
= A2
[
∂T ηm(T
∗)
ˆ t−τe
t−τe−τm
y(s) ds+ ∂T ηe(T
∗)
ˆ t
t−τe
y(s) ds
]
−
(
γP + ∂PF (P
∗)
)
x, (19)
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where
A2 =
D0VmκPQ
∗
βP
eηm(T
∗)τm+ηe(T
∗)τe . (20)
Linearizing Eq. (18) about the equilibrium yields
dy
dt
= −αTkSβPG(T
∗)x−
(
γT + αT (A1E1 + kSβPP
∗)∂TG(T
∗)
)
y
− αTA1G(T
∗)
(
∂T ηm(T
∗)
ˆ τe
0
eηe(T
∗)a
(ˆ t−a
t−a−τm
y(s) ds
)
da
+ ∂T ηe(T
∗)
ˆ τe
0
eηe(T
∗)a
(ˆ t
t−a
y(s) ds
)
da
)
,
(21)
where
A1 = VmκPQ
∗eηm(T
∗)τm and E1 =
eηe(T
∗)τe − 1
ηe(T ∗)
. (22)
4.2 Characteristic equation
The analysis above produced the linear functional equations in the variables x(t) and y(t), which are given
by Eqs. (19) and (21). The linear functional equation is written as
dX
dt
= L(X(t)), where X(t) =
(
x(t)
y(t)
)
. (23)
The characteristic equation is found by seeking solutions of the form(
x(t)
y(t)
)
=
(
c1
c2
)
eλt
and inserting this into Eq. (23). Using the results of Appendix C.1 and dividing by eλt, the linear system
becomes
λI
(
c1
c2
)
=
(
−L1 L2(λ)
L3 −L4(λ)
)(
c1
c2
)
.
The coefficients L1, L2(λ), L3, and L4(λ) are given by
L1 = γP + ∂PF (P
∗),
L2(λ) =
A2
λ
[
∂T ηm(T
∗)e−λτe
(
1− e−λτm
)
+ ∂T ηe(T
∗)
(
1− e−λτe
)]
,
L3 = −αTkSβPG(T
∗),
L4(λ) = C1 +
C2
λ
[
∂T ηm(T
∗)
(
1− e−λτm
) (1− e−(λ−ηe(T∗))τe)
(λ− ηe(T ∗))
+ ∂T ηe(T
∗)
(
eηe(T
∗)τe − 1
ηe(T ∗)
+
e−(λ−ηe(T
∗))τe − 1
λ− ηe(T ∗)
)]
,
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where
C1 = γT + αT (A1E1 + kSβPP
∗)∂TG(T
∗) and C2 = αTA1G(T
∗).
Thus, the characteristic equation is
det
∣∣∣∣−L1 − λ L2(λ)L3 −L4(λ) − λ
∣∣∣∣ = (λ+ L1)(λ+ L4(λ)) − L2(λ)L3 = 0. (24)
Appendix C.1 shows that this characteristic equation is a quartic in λ with three distinct linear polynomials
multiplying exponentials with λ and the delays. This exponential polynomial is readily programmed with
the model parameters, and numerical solutions to (24) can be found. Specifically, we find the leading pair of
complex eigenvalues, which allows for a stability analysis and to search for Hopf bifurcations.
4.3 Parameter sensitivity of the model for healthy subjects
Using the parameters from Table 1 in the characteristic equation (24), the real and imaginary parts of the
eigenvalues are found numerically. The leading pair of eigenvalues is given by λ1 = −0.058953±0.053015i,
which shows that the equilibrium state of the model is asymptotically stable.
Delay differential equations have characteristic polynomials with infinitely many eigenvalues, and we pro-
ceeded to find the eigenvalues with the next largest real part, λ2 = −0.11375± 0.3588i. Later we show how
this second pair of eigenvalues probably lead to the oscillations observed in the cyclic thrombocytopenia
patients as parameters are varied.
To provide a measure of the parameter sensitivity of the eigenvalues of our model, we varied each model
parameter by ±10% and computed how much the eigenvalues and equilibrium changed. See Tables 6 and
7 in Appendix D for the eigenvalue and equilibrium computations for these parameter changes. The tables
show that shifting any of the parameters by only 10% cannot lead to a Hopf bifurcation. In fact, these small
perturbations in the parameter values have very minimal effects on both the eigenvalues and the equilibrium.
Thus, this model is extremely stable near the set of normal parameters.
Table 6 of Appendix D shows that the leading pair of eigenvalues λ1 is most destabilized by (in descend-
ing order) increasing bP , decreasing αP , decreasing kT , increasing βP , increasing kS , increasing bm, and
decreasing Tprod. The greatest effect, however, only shifts the leading pair of eigenvalues by 11.3%. Our
study shows that changing these top seven parameters by 20% only shifts the leading pair of eigenvalues to
λ1 = −0.02555 ± 0.06563i, which still gives a stable equilibrium. It is surprising that varying the delays
has little effect on the leading pair of eigenvalues λ1.
The next largest eigenvalue, λ2, are affected most by a different set of parameters as detailed in Table 7
of Appendix D. A change of only 10% in the parameters leads to at most a 6.3% shift towards the loss of
stability associated with the Hopf bifurcation. The most destabilizing changes for this pair of eigenvalues
occur by (in descending order) increasing τe, decreasing bm, decreasing kS , increasing βP , increasing τm,
decreasing bP , and increasing γP . Note here that the model delays are significant in changing the real part
of the eigenvalues. A 20% change in these top seven parameters shifts this pair of eigenvalues to λ2 =
−0.09281± 0.3091i, which again yields a stable equilibrium. Interestingly, the frequency is moving closer
to the frequencies observed in the oscillations in the cyclic thrombocytopenia patients.
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5 Application of the model to the study of cyclic thrombocytopenia
Various modeling studies (see, e.g., [1, 8, 11–13, 47, 61]) have associated oscillations in hematological dis-
eases with a Hopf bifurcation induced by the change of one or more physiological parameters. In the context
of CT, Apostu and Mackey [1] found that changing the time for megakaryocyte maturity, reducing the rela-
tive growth rate of megakaryocytes, and increasing the random rate of destruction of platelets could generate
platelet oscillations akin to those observed in CT. Their model, however, did not include an accurate descrip-
tion of the dynamics of thrombopoietin, megakaryoblasts, and megakaryocytes, and so it is unclear if their
conclusions hold for the more physiologically realistic model presented here. In particular, the incorporation
of a dynamic equation for thrombopoietin in our model could change these conclusions, as it is believed
most platelet diseases, possibly including CT, arise due to disorders of TPO or its receptor [32].
We revisit this issue here, and use our model to investigate the pathogenesis of CT and find for which
parameters the model can generate oscillatory solutions similar to those observed in CT. We then use this
knowledge to fit the model to various platelet and TPO data sets of patients with CT.
All but one of the patient data sets in our study were found to have statistically significant oscillations
at the α = 0.05 confidence level or lower using the Lomb-Scargle periodogram technique in previous
analyses [1, 66]. The one exception, the data from Connor and Joseph [15], was published after [1] and
[66]. Therefore, we performed our own Lomb-Scargle periodogram analysis and confirmed the presence of
statistically significant oscillations at α = 0.01 (platelets) and α = 0.05 (TPO) confidence levels (data not
shown).
5.1 Parameter changes for generating periodic solutions
As discussed in Sect. 2.2, the clinical literature suggests that CT may be caused by immune-mediated
platelet destruction (autoimmune CT), megakaryocyte deficiency and cyclic failure in platelet production
(amegakaryocytic CT), or possible immune interference with or destruction of the TPO receptor. As a start-
ing point for our analysis we identify the parameters of our model that, when modified, best reproduce these
pathologies.
1. In the context of the model, we mimic an immune-mediated platelet destruction response by altering the
parameters αP , which models the maximal platelet removal rate due to macrophages.
2. To replicate the effects of megakaryocyte deficiency and cyclic failure in platelet production, we change
the value of τe, the megakaryocyte proliferation duration, while keeping the total production of megakary-
ocytes, namely ηe(T )τe, constant. Thus, whenever we scale τe by a factor of a, we scale ηmine and ηmaxe
by a factor of 1/a, thereby keeping ηe(T )τe constant. Increasing τe in this manner therefore amounts
to reducing the rate of production of megakaryocytes, mimicking an ineffective rate of production of
megakaryocytes.
3. Finally, changing αT and kT , the maximum clearance rate of thrombopoietin and TPO levels for half-
maximal removal, respectively, replicate the possible interference with or destruction of the TPO recep-
tor.
In summary, based on clinical guidance we have identified the following four parameters as likely candidates
for generating oscillations: αP , τe (and indirectly ηmine and ηmaxe ), αT , and kT .
16 G.P. Langlois et al.
Since most platelet diseases appear related to TPO or its receptor [32], we first examined the effects of
changing the values of αT and kT . We found that our model could generate oscillations when αT and kT
were significantly reduced. Oscillations were not generated when we kept αT and kT at normal levels and
changed αP and τe alone. In Fig. 2, we show the oscillations generated by our model by setting αT and
kT to 0.075% and 0.3% their normal values, respectively. Alterations to the delay τe change the period of
oscillations of both platelets and thrombopoietin, and modifying αP changes the shape of oscillations of
platelet and thrombopoietin levels (simulation data not shown).
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Fig. 2 Oscillation in platelet counts (top) and thrombopoietin (bottom) generated by our model. All pa-
rameters are at normal, except for αT and kT which are at 0.00075 and 0.003 times normal. The initial
conditions for the model are P (0) = P ∗ and T (0) = T ∗ + 100
5.2 Fitting to platelet and thrombopoietin data
As discussed in the preceding section, our model can generate oscillations by significantly reducing the
values of αT and kT . The shape and period of oscillations can be changed by modifying the values αP and
τe. With this knowledge, we now show that our model can fit platelet and TPO patient data sets of patients
with CT reported in the literature.
We fitted 15 patient data sets via a statistical procedure called the ABC method (see Appendix F for more
details on the method). The fits are shown in Figs. 3a–6c. The parameters changed to obtain these fits are
shown in Tables 2 and 3.
In every case, the parameters αT and kT had to be decreased by a significant amount to obtain the fits
(on average to 0.13512% and 0.43521% of the normal values of αT and kT , respectively). In all cases the
maximal platelet removal rate had to be increased significantly (2140.9% of normal, on average), with the
delay τe also being increased but only by a moderate amount (236.42% of normal, respectively).
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Source τe αP αT kT P ∗ T ∗ Diagnosis
Normal values 5 213 144.9 3180 31.071 100 —
Bruin et al [9] 10.552 13145 0.1365 3.8039 4.4547 90.92 Amegakaryocytic CT
Connor and Joseph [15] 12.595 726.41 0.0888 31.238 19.326 101.31 CT
Kimura et al [39] 16.491 5952.1 0.0165 8.2047 16.118 172.57 Autoimmune CT
Zent et al [78] 9.6100 2479 0.4082 13.366 5.1706 48.709 Amegakaryocytic CT
Cohen and Cooney [10] 16.5105 5455.3 0.0888 15.228 6.805 91.332 Amegakaryocytic CT
Engström et al [20] 21.034 3303.7 0.041438 15.339 11.482 114.4 Amegakaryocytic CT
Helleberg et al [31] 10.86 1253 0.33927 18.283 7.2045 51.727 Autoimmune CT
Kosugi et al [40] 10.271 2955.4 0.55513 7.4199 3.7322 34.619 Autoimmune CT
Morley [54] 9.0350 212.95 0.2513 42.825 19.162 70.831 Healthy
Rocha et al [60] 7.8029 7058.8 0.15347 11.103 6.5286 97.635 Autoimmune CT
von Schulthess and Gessner [63] (Case 1) 4.7713 1268.1 0.4565 8.2575 8.2781 60.142 Healthy
von Schulthess and Gessner [63] (Case 2) 5.9465 81.666 0.2185 2.3984 24.211 69.391 Healthy
Skoog et al [65] 10.32 9343.7 0.10981 6.3122 5.9655 101.16 Autoimmune CT
Wilkinson and Firkin [75] 24.136 5517.8 0.039057 13.648 8.6759 111.29 Amegakaryocytic CT
Yanabu et al [76] 7.381 9634.3 0.033121 10.174 13.358 177.63 Autoimmune CT
Average ± SD 11.821± 5.483 4559.1 ± 3929.2 0.19576 ± 0.17092 13.840± 10.625 10.698± 6.329 92.911 ± 41.103 —
Table 2 Parameter estimates for CT data. The fits above the double line are for patients in which both platelet counts and thrombopoietin
concentrations were available. The two columns on the right for P ∗ and T ∗ are not fits but rather predicted values from the model. All
numbers are displayed up to five significant digits
Source τe αP αT kT P ∗ T ∗ Diagnosis
Bruin et al [9] 2.1105 61.725 0.00094187 0.0011962 0.14337 0.9092 Amegakaryocytic CT
Connor and Joseph [15] 2.519 3.4111 0.00061293 0.0098234 0.62199 1.0131 CT
Kimura et al [39] 3.2981 27.95 0.00011414 0.0025801 0.51874 1.7257 Autoimmune CT
Zent et al [78] 1.922 11.641 0.0028172 0.0042033 0.16641 0.48709 Amegakaryocytic CT
Cohen and Cooney [10] 3.3021 25.617 0.00061284 0.0047887 0.21901 0.91332 Amegakaryocytic CT
Engström et al [20] 4.2069 15.514 0.00028602 0.0048236 0.36954 1.144 Amegakaryocytic CT
Helleberg et al [31] 2.172 5.8837 0.0023417 0.0057494 0.2319 0.51727 Autoimmune CT
Kosugi et al [40] 2.0543 13.878 0.0038317 0.0023308 0.12012 0.34619 Autoimmune CT
Morley [54] 1.807 1.0 0.0017347 0.013467 0.61671 0.70831 Healthy
Rocha et al [60] 1.5606 33.147 0.0010593 0.0034917 0.21011 0.97635 Autoimmune CT
von Schulthess and Gessner [63] (Case 1) 0.95425 5.9549 0.0031508 0.0025967 0.26642 0.60142 Healthy
von Schulthess and Gessner [63] (Case 2) 1.1893 0.38349 0.0015082 0.00075421 0.7792 0.69391 Healthy
Skoog et al [65] 2.0639 43.876 0.00075797 0.001985 0.19199 1.0116 Autoimmune CT
Wilkinson and Firkin [75] 4.8272 25.911 0.00026959 0.0042918 0.27922 1.1129 Amegakaryocytic CT
Yanabu et al [76] 1.4762 45.241 0.00022861 0.0031995 0.42992 1.7763 Autoimmune CT
Average ± SD 2.3642± 1.0965 21.409 ± 18.451 0.0013512 ± 0.0011797 0.0043521 ± 0.0033412 0.34431 ± 0.20371 0.92911 ± 0.41103 —
Table 3 Relative changes of parameters to normal values. All else as in Table 2.
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Fig. 3 Fits to the platelet and thrombopoietin data from: (a) Bruin et al [9]; (b) Connor and Joseph [15];
(c) Kimura et al [39]; and (d) Zent et al [78]
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Fig. 4 Fits to the platelet data from: (a) Cohen and Cooney [10]; (b) Engström et al [20]; (c) Helleberg et al
[31]; (d) Kosugi et al [40]; (e) Rocha et al [60]; and (f) Skoog et al [65]. Below each of the fitted platelet data
we show the predicted behavior of the thrombopoietin levels (which were not available for these patients)
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Fig. 4 Fits to the platelet data from: (g) Wilkinson and Firkin [75] and (h) Yanabu et al [76]
To quantify the significance of the parameter changes required in the cases of patients diagnosed with CT,
we used bootstrapping resampling techniques, which require no assumptions on the underlying distribution.
To perform the bootstrapping, we used the bootci function in MATLAB [52], which returns the sample
estimates and computes (1-α)% bootstrap confidence intervals (CIs). CIs were computed on the difference
in mean relative errors, as explained below. This construction implies that if a resulting CI contained 0, we
fail to reject the null hypothesis that there is no difference in means. In this case, we conclude that there is
no statistically significant difference in the parameter value for a healthy individual versus one with CT.
Using the average relative difference for each of the parameter values as given in Table 3, we considered the
difference between the reported value and 1 (since a relative change of 1 indicates no difference between
the healthy individual and the CT case). We then generated 10000 bootstrap estimates and computed the
bootstrap CI interval about the samples’ mean relative differences minus 1 for each parameter of interest.
The results of this analysis are given in Table 4, alongside the difference in the average relative change of
each parameter of both the fitting and bootstrap estimates and 1. In all cases, the value of the relative change
for the estimates from the fitting procedure of Sect. 5.2 and the bootstrap samples are similar (Columns 2
and 3), indicating that a sufficient number of samples was generated. None of the CIs contain 0 and therefore
we reject the null hypothesis and conclude that there are statistically significant differences at the α = 0.05
level in all cases. The resulting bootstrap confidence intervals are also reflected in Fig. 5, where the failure to
reject the null corresponds to CIs which cross the x-axis. As evidenced by the results in Table 4 and Fig. 5,
both αT and kT have particularly narrow bootstrap CIs, which suggest a higher degree of certainty in those
cases. Since we reject the null hypothesis of no difference in means for these two parameters, the narrow
CIs suggest that we are confident that there are significant differences between the CT and the healthy case.
This leads us to believe that there may be an alteration in the TPO receptor or the interaction of TPO with
the platelet lineage in patients with CT, but much more clinical investigation is required to substantiate this
conclusion.
Based on our numerical experiments and the results, the platelet and thrombopoietin oscillations in the
model occur due to a destabilization of the TPO control mechanism, in conjunction to an increased platelet-
dependent removal rate and reduced megakaryocyte production. Though the relative change of the param-
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Difference of average Difference of average 95% bootstrap CI
relative change and 1 (fit values) relative change and 1 (bootstrap values)
τe 1.6261 1.6269 [1.1418, 2.3241]
αP 25.1496 25.1180 [17.0382, 25.9115]
αT -0.9988 -0.9988 [−0.9993,−0.9980]
kT -0.9960 -0.9960 [−0.9969,−0.9943]
Table 4 Differences of relative changes and 1 for parameter values from fits of patients diagnosed with CT
and the bootstrap samples, and bootstrap 95% confidence intervals. Column 2: For each parameter fit in the
cyclic thrombocytopenic case, the difference in its relative change and 1 was calculated. Column 3: 10000
bootstrap samples were generated and the difference in the mean relative change and 1 were calculated.
Column 4: the 95% bootstrap confidence interval. CI: confidence interval
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Fig. 5 Box plots of the bootstrap confidence intervals (CIs) from fits of patients diagnosed with CT. If the
boxplot of CI of the difference in the mean bootstrap estimate and 1 crosses the dashed line, we cannot reject
the null hypothesis of no difference in mean relative error between the healthy and CT cases
eters αT and kT with the normal parameters is very large, our results are nonetheless consistent with the
clinical literature on CT.
5.3 Platelet oscillations in healthy subjects
We have also identified three published data sets indicating significant oscillations in platelets in apparently
healthy male subjects without any obvious platelet pathology [54], [63]. Interestingly in all three of these
documented cases the oscillations are in the normal range of platelet levels. We were able to fit the model to
22 G.P. Langlois et al.
these data with changes in the parameters τe, αP , αT , and kT (see Table 2 and 3) and the results of our fits
are shown in Fig. 6.
As we did in Sect. 5.2 with the patients diagnosed with CT, we used bootstrapping resampling techniques
to assess the significance of parameter changes required in these three cases. The results of this analysis are
given in Table 5 and Fig. 7. Only the CIs for αP contains 0, and therefore we reject the null hypothesis and
conclude that there are statistically significant differences at the α = 0.05 level in all other cases. We believe
that the lack of statistical significance of the changes to αP in the healthy patient cases is likely related to
small number of available datasets, as significant changes to αP were required to fit the von Schulthess and
Gessner cases. Nonetheless, we are unable to conclude that the change to αP is statistically significant in
the present study. As in the bootstrap results from the patients diagnosed with CT, both αT and kT have
narrow bootstrap CIs, which suggests a higher degree of certainty in those cases. It is possible that these
patients have an alteration in the TPO receptor or the interaction of TPO with the platelet lineage, just as
in patients diagnosed with CT. We posit that it may be that cases of oscillating platelets which do not lead
to pathological changes and that oscillations in the platelet lineage are far more common than the literature
suggests. Further clinical investigation is required, however, to validate these hypotheses.
Difference of average Difference of average 95% bootstrap CI
relative change and 1 (fit values) relative change and 1 (bootstrap values)
τe 0.3168 0.3173 [0.0326, 0.8070]
αP 1.4461 1.4572 [−0.4110, 4.9549]
αT -0.9979 -0.9979 [−0.9985,−0.9968]
kT -0.9944 -0.9944 [−0.9986,−0.9865]
Table 5 Differences of relative changes and 1 for parameter values from fits of patients displaying oscilla-
tions but diagnosed as healthy and the bootstrap samples, and bootstrap 95% confidence intervals. Column 2:
For each parameter fit, the difference in its relative change and 1 was calculated. Column 3: 10000 bootstrap
samples were generated and the difference in the mean relative change and 1 were calculated. Column 4: the
95% bootstrap confidence interval. CI: confidence interval
5.4 Hopf bifurcation for CT patients
In Sect. 4, our linear analysis, including sensitivity to perturbation of the parameters, demonstrated a strong
stability of our model for a healthy subject. The previous section provided fits to data for platelets and
TPO in CT patients, but required shifts in four parameters with some changes being quite substantial. As
the parameters are varied linearly between the two states, our numerical methods tracked the changes in
the equilibrium and the pair of eigenvalues, resulting in a Hopf bifurcation leading to the cyclic behavior
observed in the CT patients. As noted earlier, it is not the leading pair of eigenvalues for the normal parameter
set, but rather the second leading pair that results in this bifurcation.
For this section we present details from the numerics for the CT patient of Bruin et al [9]. Appendix E
includes details for the other three CT patients for which we have both platelet and thrombopoietin data.
We used our analytic techniques to follow a hyperline in the 4D-parameter space from the normal parameter
values to each of the parameter sets for the four CT patients with both platelet and TPO data, which are
listed in Table 2. The program computes the equilibrium (P ∗, T ∗) at each set of parameters along with
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Fig. 6 Fits to the platelet data from: (a) von Schulthess and Gessner [63]; (b) von Schulthess and Gessner
[63]; (c) Morley [54]. Again we show the predicted TPO variation though the data were not available
the corresponding eigenvalues. The eigenvalues are computed from the characteristic equation (24) from
Sect. 4.2. Specifically, if θ is the vector of parameters (τe, αP , αT , kT ), θhomeo is the value of that vector
of parameters at homeostasis, and θpatient is the value of the vector of parameters for the CT patient, then
θ = θhomeo + (θpatient − θhomeo)t, t ∈ [0, 1]. (25)
The results are displayed in Fig. 8.
The equilibrium for the normal parameters is (P ∗, T ∗) = (31.071, 100), while the equilibrium for the CT
patient is (P ∗, T ∗) = (4.4547, 90.92). The graphs on the left of Fig. 8 show the evolution of the equilibrium
as the parameters vary linearly from normal to the values for the CT patient. The curve moves to the left,
then starts heading toward the origin. The T ∗ value reaches a minimum slightly below with P ∗ dropping to
approximately 1.8. This curve then smoothly doubles back and passes through (P ∗, T ∗) = (1.927, 34.043),
where the Hopf bifurcation occurs and the model loses stability. Subsequently, the values of both P ∗ and
24 G.P. Langlois et al.
e P T kT
-1
0
1
2
3
4
5
Fig. 7 Box plots of the bootstrap confidence intervals (CIs) froms fits of healthy individuals displaying
oscillations in circulating platelet levels. If the boxplot of CI of the difference in the mean bootstrap estimate
and 1 crosses the x-axis, we cannot reject the null hypothesis of no difference in mean relative error between
the healthy and oscillating cases
T ∗ increase to the CT patient equilibrium with a low value of P ∗ and T ∗ around 90, which is similar to a
healthy individual.
From numerically solving Eq. (24), the eigenvalues for the normal case begin at λ = −0.11375± 0.35888i,
producing an asymptotically stable equilibrium. (We note that the leading eigenvalue for this case is λ =
−0.058953 ± 0.053015i, and it simply decreases in real and imaginary parts, becoming real along this
change of parameters.) The eigenvalues create an arc with the imaginary part decreasing, while the real
part first increases then decreases a little to a cusp-like region matching the similar region seen for the
equilibrium. The eigenvalue curve actually crosses itself before the real part increases to the Hopf bifurcation
at λ = ±0.2688i. The real part continues to increase slightly before arcing down to a lower frequency, and
the real part increases to where the equilibrium of the CT patient is unstable with λ = 0.1089 ± 0.2337i.
This frequency is consistent with a period of approximately 26.9 days, which agrees well with the observed
oscillations in the data.
Since four parameters are changing, it is hard to determine what kinetic effect is most influencing the loss
of stability. However, it is clear from our simulations that the rapid shift in equilibrium results in a quick
response of the eigenvalues. The cusp-like behavior observed is likely caused by one of the Hill functions
governing the platelet model, which could rapidly transition to a different state in the equilibrium calculation.
However, more detailed studies are needed of this phenomenon.
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Fig. 8 The curves on the left show the evolution of the equilibrium from healthy subject to CT patient as
parameters vary. The curves on the right follow the eigenvalues. The second row shows the curves magnified
6 Summary and discussion
Motivated by recent laboratory and clinical findings on thrombopoiesis in humans, we have developed a
model for the regulation of platelet production that, in contrast to previous models [1, 61], incorporates the
regulation mechanisms and dynamics of megakaryocytes and thrombopoietin. Our model of thrombopoiesis
consists of two integro-differential equations with constant delays, describing the dynamics of platelets and
thrombopoietin, and an integral equation of the dynamics of megakaryocytes in the bone marrow. As de-
scribed in Sect. 3 and Appendix A, we have estimated the parameters of the model as closely as possi-
ble from experimental and clinical data. The model has a unique positive steady state solution, which we
demonstrated in Appendix B. Furthermore, we have extended linear techniques to this complicated model
and developed numerical methods for performing a stability analysis. This analysis has provided a tool to
compare the sensitivity of the model to the many parameters and determine when stability changes occur.
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To validate our approach to model development, we applied our model to the investigation of the pathogen-
esis of cyclic thrombocytopenia. The clinical literature speculates that CT may be caused by:
1. Immune-mediated platelet destruction (autoimmune CT).
2. Megakaryocyte deficiency and cyclic failure in platelet production (amegakaryocytic CT),
3. Possible immune interference with or destruction of the TPO receptor.
The results presented in Sect. 5 indicate that highly significant reductions (factor of 1000 and 100, respec-
tively) in αT and kT , which are responsible for the platelet and megakaryocyte-dependent TPO removal
rates, are necessary to induce oscillations roughly corresponding to those of CT. Those changes were also
necessary to fit the data of Morley [54] and von Schulthess and Gessner [63], in which the apparently healthy
subjects maintain platelet levels in the normal range in the face of statistically significant oscillations. In ad-
dition, changes in τe (which represents the duration of the megakaryocyte maturation stage) as well as in
αP (which is responsible for the maximum removal rate of platelets due to macrophages) allow the accurate
replication of clinical data on platelet and thrombopoietin dynamics. (The procedure we employed to fit
the CT cases is described in detail in Appendix. F, and the numerics developed to simulate the model are
presented in Appendix G.) These changes are consistent with the results from our bootstrapping results as
well as the dependence of eigenvalue behavior that we have uncovered. Whether the changes in αT and kT
are primary, with the changes τe as well as in αP being secondary and due to an as yet unknown dynamic
interconnection, we cannot say.
While it is believed that most platelet diseases, which may include CT, arise due to disorders in TPO or its
receptor [32], we are unsure why such a significant change in αT and kT is needed to obtain oscillations.
In the context of CT, our model suggests that a disorder in TPO or its receptor (destabilized TPO removal
mechanism and decreased megakaryocyte production) along with an immune-mediated platelet destruction
response are the main causes of CT. In contrast, Apostu and Mackey [1] found that an increased random
destruction of platelets (parameter γP in this model) and decreased megakaryocyte production together
could explain the onset of oscillations. Their model, however, did not accurately describe the dynamics of
megakaryocytes and thrombopoietin. As such, our findings add further nuances to their results.
Given our current understanding of the regulation of thrombopoiesis, it is safe to say that there are unknown
biological facets of the regulatory system that are not accounted for in our model and which await further
elucidation by experimental biologists and clinicians. In addition, the mathematical analyses indicate that
there remain details in the nonlinear model, which could be explored further and possibly give insight into the
transitions from the stable normal state to the diseased state. At any rate, it is clear that a better understanding
of the mechanisms implicated in the interaction of thrombopoietin and its receptor, specifically in patients
with cyclic thrombocytopenia, will allow for further modeling refinements and a more precise picture of the
origins of this dynamical disease, and thrombopoiesis in general.
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Appendix A Parameter estimation and constraints
This extensive appendix contains the details of the parameter estimation procedure for this model largely
based on experimental data. First, in Sect. A.1 we consider the model at homeostasis. We then use TPO-
knockout experimental observations in Sect. A.2 to derive further parameter constraints. In Sect. A.3 we
provide estimates for other parameters directly from experimental data. Finally, in Sect. A.4 we calculate
remaining parameters using experimental data and the relationships derived in Sects. A.1 and A.2.
A.1 Homeostasis relationships
Let Q∗ denote the stem cell concentration, M∗e the total megakaryocyte volume, P ∗ the platelet concen-
tration, T ∗ the thrombopoietin concentration, η∗m and η∗e , the rate of mitosis and endomitosis, respectively,
and τm and τe, the average time megakaryoblasts and megakaryocytes spend in the mitotic and endomitotic
stages, respectively, at homeostasis. At this steady state, the equations for megakaryocyte production rate (3),
platelet production rate (13), megakaryocyte volume (8), platelet balance (9), and thrombopoietin balance
(10) become
m∗m(τm) = κPQ
∗eη
∗
mτm , (26)
m∗e(τe) = VmκPQ
∗eη
∗
mτm+η
∗
eτe , (27)
M∗e = VmκPQ
∗eη
∗
mτm
(
eη
∗
eτe − 1
η∗e
)
, (28)
D0
βP
m∗e(τe) = γPP
∗ + αP
(P ∗)nP
(bP )nP + (P ∗)nP
, (29)
Tprod = γTT
∗ + αT (M
∗
e + kSβPP
∗)
(T ∗)nT
(kT )nT + (T ∗)nT
. (30)
A.2 TPO knock-out relationships
The elimination of TPO gene or its receptor in mice reduces megakaryocyte and platelet levels to approxi-
mately 10% of normal [18], a finding also observed in humans (Kaushansky, private communication). There-
fore, the model must have a steady state solution at 10 % normal platelet and megakaryocyte levels when
the thrombopoietin production rate and level are both zero, giving
τem
∗
m(T = 0, τm) =
1
10
τem
∗
m(τm),
and
D0
βP
m∗e(T = 0, τe) =
1
10
γPP
∗ + αP
(P ∗)nP
(10bP )nP + (P ∗)nP
.
Using Eqs. (26) and (27), we rewrite these two relationships to obtain
eη
min
m τm =
1
10
eη
∗
mτm , (31)
D0
βP
VmκPQ
∗eη
min
m τm+η
min
e τe =
1
10
γPP
∗ + αP
(P ∗)
nP
(10bP )nP + (P ∗)nP
. (32)
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A.3 Parameters estimated from experimental data
A.3.1 Megakaryocyte compartment
Mackey [45] estimated the homeostatic concentration of HSCs using data from cats and mice, giving an
estimate of Q∗ = 1.1×106 cells/kg of body weight. We assume that humans have roughly this same number
of stem cells per kg of body weight. We estimate the parameter κP , the rate at which stem cells commit to the
megakaryocyte lineage, from the model of stem cells dynamics Mackey [45] and Bernard et al [7] developed,
and the assumption that stem cells differentiate at an equal rate into all blood lineages. This gives, to four
significant digits, an estimate of κP ≈ 0.0072419 cells/kg of body weight per day. See Craig et al [16] for
more details.
Tomer and Harker [68] measured the diameters of megakaryocytes in the bone marrow of 10 healthy indi-
viduals. They found that megakaryocytes of ploidy 2N (those megakaryocytes which have not yet undergone
endomitosis) had a mean diameter of 21± 4 µm, while the average megakaryocyte had a mean diameter of
37±4 µm. We set the average volume of a megakaryocyte of ploidy 2N to be approximately that of a sphere
with mean diameter 21 µm, and hence, set Vm = 4π(21)3/24 fL. The parameter τe, the time a megakary-
ocyte spends in endomitosis, is estimated by various sources to range from 5 to 7 days [22, 42]. We take
τe = 5 days.
A.3.2 Platelet compartment
Giles [24] measured the mean platelet count and volume in 1011 healthy human adult blood specimens.
He found the mean platelet count to be 290 × 109 platelets / L of blood and the mean platelet volume to
be 8.6 fL, so we set βP to be 8.6 fL. Since, on average, one third of the total platelet mass in the body
is sequestered by the spleen [2], we approximate the mean platelet count in the body is 1.5 times this
amount. The Hill coefficient for the platelet-dependent removal of platelets is assumed to take the value
nP = 2. Supposing that a healthy adult has roughly 5 L of blood per 70 kg of body weight gives P ∗ =
1.5× (5/70)× (290× 109) ≈ 3.1071× 1010 platelets/kg of body weight.
A.3.3 Thrombopoietin compartment
Normal TPO concentrations in humans range from 50 to 150 pg/ml of blood [42], and so we select the
middle of the range as the homeostatic concentration, T ∗ = 100 pg/ml. Since only platelets in circulation,
and not in the spleen, contribute to the binding of TPO, we set kS = 2/3, which is the fraction of the platelet
mass in circulation [2]. As there are two thrombopoietin binding sites on a TPO receptor [32], we set nT = 2
for the binding coefficient of thrombopoietin.
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A.4 Parameters calculated from experimental data and the model
A.4.1 Megakaryocyte and platelet compartments
At equilibrium, the total megakaryocyte volume is
M∗e = VmκPQ
∗eη
∗
mτm
(
eη
∗
eτe − 1
η∗e
)
, (33)
wherein η∗e = ηe(T ∗). Tomer and Harker [68] found that the average megakaryocyte in humans has a mean
diameter of 37 ± 4µm, giving an approximate mean volume of 4π(18.5)3/3 fL. Assuming the average
megakaryocyte volume predicted by our model (total volume of megakaryocytes divided by the number of
megakaryocytes) equals this value, we have from (33) that
M∗e
τem∗m(τm)
= Vm
(
eη
∗
eτe − 1
η∗eτe
)
≈
4π(37)3
24
, (34)
which can be rearranged as
eη
∗
eτe − 1
η∗eτe
=
(
37
21
)3
. (35)
Using the MATLAB [52] function fsolve, which solves the equation F (x) = 0 for x for some function F ,
we solved Eq. (35) for τeη∗e , yielding τeη∗e ≈ 2.788. Since τe is known, we have η∗e ≈ 0.5576.
Using 111In-Oxine and 111In-tropolone (more reliable markers than the previously used 51Cr label), Tsan [70]
measured the mean platelet survival time τP to be 8.4 ± 0.25 days. We assume that the platelet production
rate replenishes the full platelet population (those circulating and in the spleen) in about τP days. Therefore,
1
τP
P ∗ ≈
D0
βP
m∗e(t, τe) =
D0
βP
VmκPQ
∗eη
∗
mτm+η
∗
eτe , (36)
and, in particular,
1
τP
P ∗ = γPP
∗ + αP
(P ∗)nP
(bP )nP + (P ∗)nP
. (37)
Solving for αP , we have
αP = P
∗
(
1
τP
− γP
)(
1 +
(
bP
P ∗
)nP)
. (38)
All parameters in (38) except for bP and γP are known. The rates of removal of the platelets from the blood
should be positive, implying that γP and αP > 0. The latter requires that
1/τP − γP > 0. (39)
One megakaryocyte sheds 1000-3000 platelets [29]. Assuming, on average, that one megakaryocyte sheds
2000 platelets, then the rate of production of megakaryocytes times the number of platelets shed per megakary-
ocyte equals roughly the rate of production of platelets:
m∗m(τm)× 2000 = κPQ∗eη
∗
mτm × 2000 =
1
τP
P ∗, (40)
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giving a rate of production of megakaryocytes of 1.85 × 106 megakaryocytes/kg/day, which is close to the
value of 2×106 megakaryocytes/kg/day estimated to be the normal production rate of megakaryocytes [22].
The parameter D0, the fraction of megakaryocytes shedding platelets, can be solved for in (36) by equating
(40) with (36) and using (27). This gives
D0 = 2000
βP
Vm
e−η
∗
eτe ≈ 0.21829. (41)
Rearranging (40) and solving for η∗mτm, we get
η∗mτm = ln
(
1
2000
1
κPQ∗
1
τP
P ∗
)
≈ 5.4394.
Substituting in Eq. (31) and solving for ηmin∗ , we have
ηminm =
1
τm
ln
(
1
20000
1
κPQ∗
1
τP
P ∗
)
. (42)
Using Eq. (1) at homeostasis to solve for ηmaxm in Eq. (31) gives
ηmaxm = η
min
m +
ln(10)
τm
(
1 +
bm
T ∗
)
. (43)
We can now use the steady state equation for the platelet numbers in absence of thrombopoietin, Eq. (32), in
combination with the expressions (40) and (41) to get
1
10τP
P ∗e(η
min
e −η
∗
e )τe =
1
10
γPP
∗ + αP
(P ∗)nP
(10bP )nP + (P ∗)nP
.
Solving for ηmine − η∗e , we get
ηmine = η
∗
e +
1
τe
ln
[
τP γP + 10τPαP
(P ∗)nP−1
(10bP )nP + (P ∗)nP
]
. (44)
We can solve for ηmaxe via Eq. (5) at steady state:
ηmaxe = η
min
e + (η
∗
e − η
min
e )
(
1 +
be
T ∗
)
. (45)
A.4.2 Thrombopoietin compartment
Using Eq. (30), the homeostasis relationship for the thrombopoietin concentration, we can solve for αT ,
yielding
αT =
Tprod − γTT
∗
M∗e + βPP
∗
(
1 +
(
kT
T ∗
)nT)
. (46)
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A.5 Parameters fit from experimental data
From the above calculations, it remains to estimate eight more parameters: τm, bm, be, γP , bP , Tprod, γT ,
and kT . The first five parameters pertain to megakaryocyte and platelet dynamics, while the last three pertain
to thrombopoietin dynamics.
We digitized data from Wang et al [72] for the circulating platelet and TPO levels in healthy patients follow-
ing a 1µg/kg of bodyweight intravenous infusion of Romiplostim, a TPO mimetic with similar physiological
activity to TPO. We then fitted the parameters by simulating the response of our model (11)–(14) to an infu-
sion of 1µg/kg of TPO and minimizing the squared error between data and simulation.
Specifically, the platelet and TPO data points (and error bars, when available) were interpolated and evalu-
ated at 1000 points in each time interval (ranging from 0 to 42 days for the platelet data and 0 to 1 day for
the TPO data), yielding the vectors of points Pdata and Tdata. To simulate the response of our model to a
1µg/kg intravenous infusion of thrombopoietin, we ran the numerical algorithm described in Appendix G
with initial history functions (Ph, Th) = (P ∗, T ∗) and initial conditions P0 = P ∗ and T0 = Tdata(t = 0).
We then evaluated the solution of our model at the interpolated points Pdata and Tdata to obtain the model
points Pmodel and Tmodel, respectively.
For parameter estimation, we minimized the fitting error
Err =
‖ 23Pmodel(t)−Pdata‖2
max(Pdata)
+
‖Tmodel −Tdata‖2
max(Tdata)
, (47)
by using the fmincon function in MATLAB [52] to find the set of parameters that minimizes (47). (The factor
of 2/3 accounts for the fraction of platelets that circulate in blood in our model.) The fit obtained from this
procedure is shown in Fig. 9.
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Fig. 9 Fit of our model to the platelet and thrombopoietin data from Wang et al [71] following a 1µg/kg
intravenous infusion of TPO
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Appendix B Proof of existence and uniqueness of a positive steady state solution
Here, we prove that the model has a unique, positive steady state solution by showing that Eqs. (9) and (10)
have a unique positive fixed point.
As discussed in Appendix A, Eqs. (9) and (10) at steady state (homeostasis) are given by
D0
βP
m∗e(T
∗, τe) = γPP
∗ + αP
(P ∗)nP
(bP )nP + (P ∗)nP
, (48)
and
Tprod = γTT
∗ + αT (M
∗
e (T
∗) + kSβPP
∗)
(T ∗)nT
(kT )nT + (T ∗)nT
, (49)
where
m∗e(T
∗, τe) = VmκPQ
∗eη
∗
m(T
∗)τm+η
∗
e (T
∗)τe ,
M∗e (T
∗) = VmκPQ
∗eτmη
∗
m(T
∗)
(
eη
∗
e (T
∗)τe − 1
η∗e (T
∗)
)
,
ηm(T (t)) = η
min
m + (η
max
m − η
min
m )
T
bm + T
,
and
ηe(T (t)) = η
min
e + (η
max
e − η
min
e )
T
be + T
.
Unlike most population and blood cell regulation models, notice that (P ∗ = 0, T ∗ = 0) is not an equilibrium
of Eqs. (48) and (49). This is because of the nonzero constant production rate of thrombopoietin reflected in
the first term of (49), and is analogous to infectious disease models for which there is a constant influx of
susceptibles (see, for example, Sect. 2.1.2 of Keeling and Rohani [38]).
Although finding (P ∗, T ∗) involves solving two highly nonlinear equations in two unknowns, we can use
Eq. (49) to solve for P ∗ explicitly in terms of T ∗, yielding
P ∗ =
1
kSβP
[
Tprod − γTT
∗
αT
(
1 +
(
kT
T ∗
)nT)
−VmκPQ
∗eη
∗
m(T
∗)τm
(
eη
∗
e (T
∗)τe − 1
η∗e(T
∗)
)]
.
(50)
Denote the right-hand-side of Eq. (50) by L(T ∗). Writing
L1(T
∗) =
Tprod − γTT
∗
αT
(
1 +
(
kT
T ∗
)nT)
and
L2(T
∗) = VmκPQ
∗eη
∗
m(T
∗)τm
(
eη
∗
e (T
∗)τe − 1
η∗e(T
∗)
)
,
we can rewrite Eq. (50) as
P ∗ = L(T ∗) =
1
kSβP
[L1(T
∗)− L2(T
∗)] .
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We now show that L is a monotone decreasing function of T ∗, and thus defines an injective function of
P ∗. First, notice that L1 is a monotone decreasing function of T ∗, approaching +∞ as T ∗ → 0, becoming
negative-valued when T ∗ > Tprod/γT , and approaching −∞ as T ∗ → ∞. Second, as both ηm(T ∗)
and ηe(T ∗) are monotone increasing in T ∗ (taking values in the intervals (ηminm , ηmaxm ) and (ηmine , ηmaxe ),
respectively), the terms
VmκPQ
∗eη
∗
m(T
∗)τm and e
η∗e (T
∗)τe − 1
η∗e(T
∗)
in L2(T ∗) are both monotone increasing whenever τeη∗e (T ∗) > 0, which holds by definition in our model.
As L2 is the product of two monotone increasing functions, it is also a monotone increasing function. Taken
together, these results show that L defines an injective function of P ∗.
Now consider Eq. (48) and denote its left-hand-side and right-hand-side by g(T ∗) and h(P ∗), respectively.
The function h is clearly monotone increasing in P ∗, starting from 0 and approaching +∞ as P ∗ → ∞.
Using the previous argument on η∗m(T ∗) and η∗e (T ∗), we have that g is a monotone increasing function of
T ∗ and uniformly bounded above and below by
D0VmκPQ
∗
βP
eη
min
m τm+η
min
e τe ≤ g(T ∗) ≤
D0VmκPQ
∗
βP
eη
max
m τm+η
max
e τe .
Finding a positive stationary solution in (P ∗, T ∗) therefore amounts to finding a value of T ∗ satisfying
h(L(T ∗)) = g(T ∗) (51)
and then defining the corresponding value of P ∗ being given by Eq. (50). As h(L(T ∗)) is monotone decreas-
ing from +∞ to negative values and g(T ∗) is monotone increasing between two positive values, there is a
unique positive solution to Eq. (51). That is, Eqs. (17) and (18) have a unique positive steady state solution
(P ∗, T ∗).
Appendix C Linearization of the thrombopoiesis equations and bifurcation analysis
We take the model in Sect. 4, which has a differential equation for the platelets, (17), and one for the
thrombopoietin, (18), depending only on P and T . From Appendix. B, the model has a unique positive
equilibrium, (P ∗, T ∗). Linearizing about the equilibrium, we let x(t) = P (t)− P ∗ and y(t) = T (t)− T ∗.
We use Taylor expansions for both the exponential function and ηm(T (s)) to obtain the following linear
approximation:
exp
[ˆ t−τe
t−τe−τm
ηm(T (s)) ds
]
≈ exp
[ˆ t−τe
t−τe−τm
(ηm(T
∗) + ∂T ηm(T
∗)y(s)) ds
]
= eηm(T
∗)τm exp
[
∂T ηm(T
∗)
ˆ t−τe
t−τe−τm
y(s) ds
]
≈ eηm(T
∗)τm
(
1 + ∂T ηm(T
∗)
ˆ t−τe
t−τe−τm
y(s) ds
)
.
Similarly,
exp
[ˆ t
t−τe
ηe(T (s)) ds
]
≈ eηe(T
∗)τe
(
1 + ∂T ηe(T
∗)
ˆ t
t−τe
y(s) ds
)
,
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exp
[ˆ t−a
t−a−τm
ηm(T (s)) ds
]
≈ eηm(T
∗)τm
(
1 + ∂T ηm(T
∗)
ˆ t−a
t−a−τm
y(s) ds
)
,
and
exp
[ˆ t
t−a
ηe(T (s)) ds
]
≈ eηe(T
∗)a
(
1 + ∂T ηe(T
∗)
ˆ t
t−a
y(s) ds
)
.
Linearizing the integral product in Eq. (18), we obtain the following approximation:
ˆ τe
0
exp
[ˆ t−a
t−a−τm
ηm(T (s)) ds
]
exp
[ˆ t
t−a
ηe(T (s)) ds
]
da
≈
ˆ τe
0
eηm(T
∗)τm+ηe(T
∗)a
(
1 + ∂T ηm(T
∗)
ˆ t−a
t−a−τm
y(s) ds
)(
1 + ∂T ηe(T
∗)
ˆ t
t−a
y(s) ds
)
da
≈ eηm(T
∗)τm
[
eηe(T
∗)τe − 1
ηe(T ∗)
+ ∂T ηm(T
∗)
ˆ τe
0
eηe(T
∗)a
(ˆ t−a
t−a−τm
y(s) ds
)
da
+ ∂T ηe(T
∗)
ˆ τe
0
eηe(T
∗)a
(ˆ t
t−a
y(s) ds
)
da
]
.
These results can be used to find the linearization of the platelet and thrombopoietin equations. The platelet
equation with only the constant and linear terms (higher order terms dropped) is given by
dx
dt
= A2
[
1 + ∂T ηm(T
∗)
ˆ t−τe
t−τe−τm
y(s) ds+ ∂T ηe(T
∗)
ˆ t
t−τe
y(s) ds
]
− γP (x+ P
∗)−
(
F (P ∗) + ∂PF (P
∗)x
)
,
(52)
where
A2 =
D0VmκPQ
∗
βP
eηm(T
∗)τm+ηe(T
∗)τe .
The thrombopoietin equation can be written as
dy
dt
= Tprod − γT (y + T
∗)− αT
(
A1
[
E1 + ∂T ηm(T
∗)
ˆ τe
0
eηe(T
∗)a
(ˆ t−a
t−a−τm
y(s) ds
)
da
+ ∂T ηe(T
∗)
ˆ τe
0
eηe(T
∗)a
(ˆ t
t−a
y(s) ds
)
da
]
+ kSβP (x + P
∗)
)
(G(T ∗) + ∂TG(T
∗)y),
where
A1 = VmκPQ
∗eηm(T
∗)τm and E1 =
eηe(T
∗)τe − 1
ηe(T ∗)
.
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The thrombopoietin equation with only the constant and linear terms (higher order terms dropped) is given
by:
dy
dt
= Tprod − γT (y + T
∗)− αT
[
(A1E1 + kSβPP
∗)G(T ∗) + (A1E1 + kSβPP
∗)∂TG(T
∗)y
+ kSβPG(T
∗)x+ A1G(T
∗)
(
∂T ηm(T
∗)
ˆ τe
0
eηe(T
∗)a
(ˆ t−a
t−a−τm
y(s) ds
)
da
+ ∂T ηe(T
∗)
ˆ τe
0
eηe(T
∗)a
(ˆ t
t−a
y(s) ds
)
da
)]
,
(53)
By the definition of an equilibrium, the constant terms in Eqs. (52) and (53) sum to zero, yielding the linear
equations for platelets, (19), and thrombopoietin, (21), given in Sect. 4.1.
C.1 Details for the characteristic equation
We examine the integral terms in Eqs. (19) and (21), using the exponential form for y(t) = eλt. There are
four integrals, which we evaluate below:ˆ t−τe
t−τe−τm
eλs ds =
eλ(t−τe)
λ
(
1− e−λτm
)
,
ˆ t
t−τe
eλs ds =
eλt
λ
(
1− e−λτe
)
,
ˆ τe
0
eηe(T
∗)a
(ˆ t−a
t−a−τm
eλs ds
)
da =
eλt
(
1− e−λτm
)
λ(λ− ηe(T ∗))
(
1− eηe(T
∗)τe−λτe
)
,
and ˆ τe
0
eηe(T
∗)a
(ˆ t
t−a
eλs ds
)
da =
eλt
λ
(
eηe(T
∗)τe − 1
ηe(T ∗)
+
e−(λ−ηe(T
∗))τe − 1
λ− ηe(T ∗)
)
.
These expressions are used in the terms L2(λ) and L4(λ) in the characteristic equation for the linear func-
tional Eq. (23).
If Eq. (24) is multiplied by λ(λ − ηe), then the terms in the denominator can be eliminated (at the expense
of introducing the roots λ = 0 and ηe). The first polynomial piece becomes
(λ+ L1)(λ+ C1)λ(λ − ηe) = λ
4 + (L1 + C1 − ηe)λ
3 + (L1C1 − (L1 + C1)ηe)λ
2 − L1C1ηeλ.
Next we consider the portion L4(λ) − C1 in (24)
(L4(λ) − C1)λ(λ− ηe) = C2∂T∂T ηm(T
∗)
(
1− e−λτm
) (
1− e−(λ−ηe)τe
)
+ C2∂T ηe(T
∗)
(
eηeτe − 1
ηe
(λ− ηe) + (e
−(λ−ηe)τe − 1)
)
= C2∂T ηm(T
∗)
(
1− e−λτm − eηeτee−λτe + eηeτee−λ(τe+τm)
)
+ C2∂T ηe(T
∗)
(
eηeτe − 1
ηe
)
(λ− ηe) + C2∂T ηe(T
∗)(eηeτee−λτe − 1).
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We take the previous expression and multiply by λ+ L1 and define
D1 =
C2∂T ηe(T
∗) (eηeτe − 1)
ηe
, D2 = C2e
ηeτe(∂T ηe(T
∗)−∂T ηm(T
∗)), and D3 = C2e
ηeτe∂T ηm(T
∗).
The results are
(λ+ L1)(L4(λ) − C1)λ(λ − ηe) = (λ+ L1) (C2∂T ηm(T
∗) +D1(λ− ηe)− C2∂T ηe(T
∗))
− (λ+ L1)C2∂T ηm(T
∗)e−λτm + (λ+ L1)D2e
−λτe + (λ+ L1)D3e
−λ(τe+τm)
and
L2(λ)L3λ(λ−ηe) = L3(λ−ηe)A2
(
∂T ηm(T
∗)e−λτe − ∂T ηm(T
∗)e−λ(τe+τm) + ∂T ηe(T
∗)− ∂T ηe(T
∗)e−λτe
)
.
Multiplying by λ(λ − ηe) produces a quartic exponential polynomial in the eigenvalues, which can be
analyzed using techniques we have developed earlier [46]. The characteristic equation can be written as
λ4 +K3λ
3 +K2λ
2 +K1λ+K0 + (α1λ+ α0)e
−λτm
+(β1λ+ β0)e
−λτe + (γ1λ+ γ0)e
−λ(τe+τm) = 0.
We examine the terms above and obtain the following coefficients:
K0 = L1C2(∂T ηm(T
∗)− ∂T ηe(T
∗))−D1L1ηe + L3A2∂T ηe(T
∗)ηe,
K1 = −L1C1ηe + C2(∂T ηm(T
∗) + ∂T ηe(T
∗) +D1(L1 − ηe)− L3A2∂T ηe(T
∗),
K2 = L1C1 − (L1 + C1)ηe +D1,
K3 = L1 + C1 − ηe,
α0 = −C2∂T ηm(T
∗)L1,
α1 = −C2∂T ηm(T
∗),
β0 = D2L1 − L3A2ηe(∂T ηe(T
∗)− ∂T ηm(T
∗)),
β1 = D2 + L3A2(∂T ηe(T
∗)− ∂T ηm(T
∗)),
γ0 = D3L1 + L3A2ηe∂T ηm(T
∗)
γ1 = D3 − L3A2∂T ηm(T
∗).
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Appendix D Parameter sensitivity of the model for healthy subjects
The characteristic equation (24) from the linear analysis is used to study the sensitivity of each parameter
near its normal value. We developed MATLAB programs from the linear analysis to compute the leading
eigenvalues of the model. With the normal parameters of Table 1 we obtained the equilibrium (P ∗, T ∗) =
(31.071, 100), which has the leading pair of eigenvalues λ1 = −0.058953± 0.053015i. It follows that the
model with these eigenvalues is asymptotically stable. It should be noted that the frequency is equivalent to
a period of 118.5 days, which is far from the observed oscillation periods in either the healthy subjects or
patients with cyclic thrombocytopenia.
To analyze the sensitivity of the model to the various parameters, we used our MATLAB code to find the new
equilibrium and leading eigenvalues as we varied each parameter by±10%. Table 6 gives a complete listing
of how the equilibrium changes and leading eigenvalues shifts with all of the individual parameter changes.
We are most interested in stability changes, so the lowest ratio of the real part of the leading eigenvalues
gives the largest change in the direction of a Hopf bifurcation.
P ∗ T ∗ Real Imag ratio Re ratio Im
Normal 31.071 100.0 -0.058953 0.053015
bP -10% 29.0196 100.9495 -0.067296 0.043747 1.142 0.825
bP +10% 32.8346 99.3905 -0.052283 0.058441 0.887 1.102
αP -10% 32.0273 99.7183 -0.055079 0.056355 0.934 1.063
αP +10% 30.0968 100.5067 -0.062686 0.049258 1.063 0.929
γP -10% 31.7203 99.8432 -0.058229 0.053277 0.988 1.005
γP +10% 30.3240 100.4136 -0.059747 0.052683 1.013 0.994
κP -10% 30.0012 102.4043 -0.057024 0.055546 0.967 1.048
κP +10% 31.9549 98.1063 -0.06075 0.050488 1.030 0.952
βP -10% 33.3576 100.5375 -0.062871 0.049083 1.066 0.926
βP +10% 29.0111 99.7651 -0.055601 0.055916 0.943 1.055
αT -10% 32.2845 102.8172 -0.060871 0.052074 1.033 0.982
αT +10% 29.9044 97.7452 -0.057327 0.053726 0.972 1.013
kT -10% 28.6234 94.9109 -0.055442 0.054430 0.940 1.027
kT +10% 33.3536 105.0196 -0.062445 0.051155 1.059 0.965
γT -10% 31.0302 100.1744 -0.058994 0.053038 1.001 1.000
γT +10% 30.9910 100.0910 -0.058940 0.052996 1.000 1.000
Tprod -10% 29.7700 97.4513 -0.056887 0.053955 0.965 1.018
Tprod +10% 32.1795 102.5986 -0.060925 0.052003 1.033 0.981
kS -10% 31.5216 101.2177 -0.062364 0.045469 1.058 0.858
kS +10% 30.5245 99.0902 -0.055813 0.058817 0.947 1.109
be -10% 31.4498 99.4983 -0.059528 0.052684 1.010 0.994
be +10% 30.6166 100.7105 -0.058451 0.053328 0.991 1.006
bm -10% 33.1719 95.6242 -0.062519 0.051101 1.060 0.964
bm +10% 29.2024 104.2848 -0.056023 0.054177 0.950 1.022
τm -10% 31.0106 100.1327 -0.057789 0.060694 0.980 1.145
τm +10% 31.0106 100.1327 -0.059777 0.045867 1.014 0.865
τe -10% 31.7286 101.6540 -0.059127 0.057713 1.003 1.089
τe +10% 30.3550 98.7243 -0.058709 0.048716 0.996 0.919
Table 6 Parameter sensitivity to changes in the normal parameters of the leading pair of eigenvalues λ1
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For the sensitivity analysis, if we only consider the movement of the leading pair of eigenvalues toward the
imaginary axis, then the smallest values in the 7th column (ratio Re) give the greatest shift toward instability.
The parameter changes that destabilize the model most are (in descending order) increasing bP , decreasing
αP , decreasing kT , increasing βP , increasing kS , increasing bm, and decreasing Tprod.
As an experiment to extend this analysis, we chose to increase or decrease all seven of these parameters by
20% to see what happened to the equilibrium and the leading eigenvalues. The result of all seven changes re-
sulted in the equilibrium (P ∗, T ∗) = (20.772, 85.117) and leading eigenvalues λ1 = −0.02555±0.06563i.
We note that this more than halves the distance of the real part toward the imaginary axis, and also the
frequency shifts the period to 95.74 days.
The analysis shows that near normal, there are several parameters to which the model is very insensitive.
Surprisingly, this includes all of the delay parameters, τe and τm. It is also quite insensitive to changes in
γP , γT , and be. However, our numerical study shows that τe and τm can have effects on the imaginary part.
This analysis shows that the leading eigenvalues have the wrong frequency for the observed oscillations
in cyclic thrombocytopenia patients. This suggests the need to examine the next, second leading pair of
eigenvalues for this model. Its frequency is closer to the range of interest and provides a starting point for
a Hopf bifurcation study of our cyclic thrombocytopenia patients. Again, with the normal parameters the
second eigenvalues are λ2 = −0.11375 ± 0.35888i, which gives a quasiperiod near 17.5 days. Table 7
shows the effects on this pair of eigenvalues as the parameters are changed by ±10%.
For the sensitivity analysis, we examine the movement of the second leading pair of eigenvalues, λ2, toward
the imaginary axis. Again, the smallest values in the 7th column (ratio Re) give the greatest shift toward
instability. The most destabilizing changes for this pair of eigenvalues occur by (in descending order) in-
creasing τe, decreasing bm, increasing kS , increasing βP , increasing τm, decreasing bP , and decreasing γP .
We note that the delays τe and τm affect the movement of the real part of these eigenvalues.
To extend this analysis, we chose to increase or decrease all seven of these parameters by 20% to see what
happened to the equilibrium and eigenvalues. The result of all seven changes resulted in the equilibrium
(P ∗, T ∗) = (26.505, 87.236) and eigenvalues λ2 = −0.09281± 0.3091i. Note that the distance of the real
part toward the imaginary axis is slightly more than for the leading pair with its most significant parameters,
and also the frequency shifts the period to 20.33 days.
Appendix E Hopf bifurcation for CT patients
This appendix continues the studies of the CT patients from Sect. 5.4. The four parameters are varied lin-
early between the normal state and the best fitting parameters for several CT patients. Again, our numerical
methods tracked the changes in the equilibria and the pairs of eigenvalues, which result in Hopf bifurcations
leading to the cyclic behavior observed in the CT patients.
Table 2 in Sect. 5.2 shows the best parameter fit to τe, αP , αT , and kT for the CT patients of Connor and
Joseph [15], Kimura et al [39], and Zent et al [78]. As was done with the CT patient of Bruin et al [9] in
Sect. 5.4, a hyperline in the 4D-parameter space from the normal parameter values to each of the parameter
sets for these three CT patients was followed, and the numerical values of the equilibrium (P ∗, T ∗) and
eigenvalues λ were tracked at each set of parameter values. As before, the eigenvalues tracked were the ones
from the second leading pair of the healthy subject, which is the pair that undergoes a Hopf bifurcation as
the hyperline extends to any of the CT patients. The results are displayed in Fig. 10.
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P ∗ T ∗ Real Imag ratio Re ratio Im
Normal 31.071 100 -0.11375 0.35888
bP -10% 29.0196 100.9495 -0.11375 0.3588 0.974 1.001
bP +10% 32.8346 99.3905 -0.11949 0.3577 1.024 0.998
αP -10% 32.0273 99.7183 -0.11826 0.35796 1.013 0.999
αP +10% 30.0968 100.5067 -0.11536 0.35853 0.988 1.001
γP -10% 31.7203 99.8432 -0.11799 0.35806 1.011 0.999
γP +10% 30.324 100.4136 -0.11551 0.35847 0.990 1.001
κP -10% 30.0012 102.4043 -0.11561 0.35761 0.990 0.998
κP +10% 31.9549 98.1063 -0.11776 0.35886 1.009 1.002
βP -10% 33.3576 100.5375 -0.11524 0.35855 0.987 1.001
βP +10% 29.0111 99.7651 -0.11809 0.358 1.012 0.999
αT -10% 32.2845 102.8172 -0.11411 0.35789 0.978 0.999
αT +10% 29.9044 97.7452 -0.11912 0.35858 1.020 1.001
kT -10% 28.6234 94.9109 -0.12202 0.35892 1.0453 1.002
kT +10% 33.3536 105.0196 -0.11204 0.35756 0.960 0.998
γT -10% 31.0302 100.1744 -0.11662 0.35831 0.999 1.000
γT +10% 30.991 100.091 -0.11684 0.35823 1.001 1.000
Tprod -10% 29.77 97.4513 -0.11874 0.35543 1.017 0.992
Tprod +10% 32.1795 102.5986 -0.11491 0.3607 0.984 1.007
kS -10% 31.5216 101.2177 -0.112 0.35762 0.959 0.998
kS +10% 30.5245 99.0902 -0.12118 0.35899 1.038 1.002
be -10% 31.4498 99.4983 -0.11717 0.35822 1.004 1.000
be +10% 30.6166 100.7105 -0.11632 0.35828 0.996 1.000
bm -10% 33.1719 95.6242 -0.11169 0.36068 0.957 1.007
bm +10% 29.2024 104.2848 -0.12133 0.35606 1.039 0.994
τm -10% 31.0106 100.1327 -0.12172 0.37874 1.043 1.057
τm +10% 31.0106 100.1327 -0.11224 0.33985 0.962 0.949
τe -10% 31.7286 101.654 -0.12517 0.37101 1.072 1.036
τe +10% 30.355 98.7243 -0.10939 0.34619 0.937 0.966
Table 7 Parameter sensitivity to changes in the normal parameters of the second leading pair of eigenvalues
λ2
The equilibrium for the normal parameter set is (P ∗, T ∗) = (31.071, 100.00). As the parameter sets move
along each of the hyperlines, the equilibria first shift slowly in an arc toward the origin. For all of our
examples, this first arc of equilibria takes over 98% of the hyperline, that is, in Eq. (25) if the arc is created
by t ∈ [0, t1), then t1 > 0.98. For an unknown reason (likely a transition in one of the Hill functions), the
equilibrium rapidly shifts away from this slow path toward the origin along a different trajectory. This new
direction roughly doubles back, but heads to the different states of equilibria for each of the different patients.
It is along this rapidly evolving path that the Hopf bifurcation occurs. Fig. 10 (and Fig. 8) shows that the
cusp-like behavior is similar in all cases, but the evolving paths are distinct for each patient. This complicates
the interpretation of how the cyclic thrombocytopenia is explained through the parameters. Table 8 gives the
values for the equilibria of the Hopf bifurcation along with the equilibria for the best fitting parameters of
the different CT patients.
We numerically solve Eq. (24), starting at the eigenvalues for the normal case with λ = −0.11375±0.3588i.
In all cases, the eigenvalues create an arc with the imaginary part decreasing, while the real part first increases
then decreases. This arc is created quite slowly and follows the slowly evolving equilibria above. When
the equilibria start evolving rapidly, the values of the eigenvalues rapidly shift with increasing real part.
Specifically, the real part turns around and increases very rapidly to the Hopf bifurcation. The different CT
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Fig. 10 The curves on the left show the evolution of the equilibrium from healthy subject to CT patient
as parameters vary. The curves on the right follow the eigenvalues. The rows represent the evolution from
healthy subject to the CT patients of Connor and Joseph [15], Kimura et al [39], and Zent et al [78], respec-
tively
patients have slightly different changes in their eigenvalues, particularly in what happens to the imaginary
part. All cases of the CT patients have their eigenvalues with positive real part, which is to be expected. The
frequency of the eigenvalues varies from 0.1641 to 0.2698, yielding periods in the range of 23.3 to 38.3
days, which are consistent with the simulations in Sect. 5.2.
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(P ∗
h
, T ∗
h
) λh (P
∗
e , T
∗
e ) λe
Connor (10.118, 59.244) ±0.2311i (19.326, 101.31) 0.07348 ± 0.2111i
Kimura (2.809, 35.484) ±0.2000i (16.118, 172.57) 0.08832 ± 0.1641i
Zent (4.286, 38.329) ±0.2798i (5.1706, 48.709) 0.06605 ± 0.2698i
Table 8 The second and third columns give the equilibria and eigenvalues at the Hopf bifurcation. The
fourth and fifth columns give the equilibria and eigenvalues for the specific CT patient
Appendix F Fitting of cyclic thrombocytopenia patient data
In this appendix, we describe the statistical procedure used in Sect. 5 to fit the parameters τe, αP , αT , and
kT of our model to 15 published platelet and TPO data sets of patients with CT [9, 10, 15, 20, 31, 39, 40, 54,
60, 63, 65, 75, 76, 78]. Of these 15 data sets, only four contained both platelet and TPO data [9, 15, 39, 78].
We chose to analyze data sets of untreated CT patients only, as treatments may have altered platelet or TPO
dynamics or both and is thus outside the scope of this model.
We first introduce some notation before describing the ABC-MCMC algorithm and the fitting procedure [49].
Let θ be the vector of all the parameters, that is, θ = (τe, αP , αT , kT )⊤. Let D denote the observed data,
including Pdata and Tdata. LetD
′ denote the model response, including Pmodel and Tmodel. Let ρ(D
′
,D)
denote the distance between D′ and D. Let ǫ be a prefixed threshold. The gist of the fitting procedure for a
data set is as follows.
1. Choose an initial set of values of parameters for θ.
2. Propose a move from the current value of θ to θ
′
according to a transition kernel q(·|θ).
3. Simulate D′ using the model with parameters θ
′
.
4. If ρ(D′ ,D) 6 ǫ, go to step 5, and otherwise stay at θ and return to step 2.
5. Calculate
α(θ, θ
′
) = min
(
1,
π(θ
′
)q(θ|θ
′
)
π(θ)q(θ
′
|θ)
)
,
update θ to θ
′
with this probability, and store the value of θ
′
.
6. Repeat steps 2-5 using θ′ as the new initial set of values of parameters for a sufficient number of times,
and finally pick θ′ that minimizes ρ(D′ ,D) among all stored values of θ′.
To measure the distance between the simulated data D′ and the observed data D, we use the following sum
of squared errors (SSE):
ρ(D
′
,D) =
‖ 23Pmodel −Pdata‖2
‖Pdata‖2
+
‖Tmodel −Tdata‖2
‖Tdata‖2
, (54)
where the factor of 2/3 accounts for the fraction of platelets that circulate in blood in our model.
For the fits in this paper, in step 1 we chose the initial parameters so that the model generated oscillations,
as discussed in Sect. 5.1, and gave a rough approximation to the data set. These parameters defined the
initial data D, and the initial SSE was computed using Eq. (54). We fixed the threshold ǫ to 1.15 times the
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initial SSE and computed steps 2-5 for 250 successful iterations before choosing the vector of parameters θ
minimizing ρ(D′ ,D).
In step 5 of the ABC-MCMC implementation, we use a uniform distribution as the prior distribution for
the parameters, which leads to π(θ
′
)/π(θ) = 1. In addition, we choose a Gaussian distribution to be the
transition kernel, which implies q(θ|θ
′
)/q(θ
′
|θ) = 1. As a result, α(θ, θ
′
) is simplified to 1.
The stationary distribution of the MCMC chain is the posterior distribution of the parameters given the
simulated data are close enough to the observed data (ρ(D′ ,D) 6 ǫ). In other words, with a good initial
choice of parameter values, this ABC-MCMC algorithm guarantees convergence to a good fit.
Appendix G Numerical Analysis
Numerical simulations of the system of equations (12) and (13) are necessary both to illustrate results for any
parameter set, and also as part of the parameter fitting described in Appendix F. Accurate numerical solution
of these equations is complicated by their structure as distributed delay differential equations (DDEs) with
the terms me(t, τe) and Me(t) both defined by integrals of the solution functions from time t − τe − τm to
t, with Me(t) requiring the computation of the integral of the product of the exponential of two integrals.
Traditional Runge-Kutta methods for ordinary differential equations (ODEs) only define a numerical approx-
imation to the solution on a discrete set of time points. This is problematical when the solution is required at
off mesh time values, which arises for example for the accurate evaluation of integrals, as is the case in our
problem. Continuous Runge-Kutta (CRK) methods were developed [4, 28] to produce continuous output
suitable for the numerical solution of both ODEs and DDEs. These are the methods currently most often
used to solve discrete DDEs, with the Matlab [52] software package containing built in functions (dde23,
ddesd) for the solution of discrete constant delay and state-dependent variable delay DDEs. However, these
methods are not appropriate for problems with vanishing or distributed delays, because they become fully
implicit. To see how this arises suppose the system (12)–(13) is already solved up to time tn and consider
the computation of the next step. To compute the jth stage of the CRK method for the next step requires
the computation of the right-hand side of the system of equations at time tn + cjh, where h = tn+1 − tn is
the step-size of the method and the cj are the abscissa of the CRK method. But this requires us to evaluate
me(tn + cjh, τe) and Me(tn + cjh), for which we need integrals of T (t) up to time tn + cjh, but until
all the stages of the current step are computed we only have the solution of T (t) available up to time tn.
This problem does not arise in the first order forward Euler method (which has just one stage with c1 = 0),
but all higher order CRK methods become fully implicit. Ad-hoc methods for approximating the missing
integral result in a reduction in the order of the method, and so the only CRK methods that are appropriate
for our problem are the first order forward Euler method or higher order implicit methods. To obtain accurate
solutions efficiently we do not use such methods.
Methods that remain explicit for distributed DDEs and DDEs with vanishing delays were first proposed by
Tavernini [67], and have more recently been developed into a class of methods called Functional Continuous
Runge-Kutta (FCRK) methods [6, 50]. In Bellen [5] it was proposed to apply FCRK methods to distributed
DDEs in biomathematics, but we are not aware of any implementation of FCRK methods for distributed
DDEs before the current work.
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To solve the system (12)–(13) we implemented the explicit two-stage second order Heun FCRK method
proposed in [17]. This has Butcher tableau
c A(α)
b(α)
=
0 0 0
1 α 0
α− 12α
2 1
2α
2
which defines the parameters ci, bi(α) and aij(α) in the explicit FCRK method
Ki = hG(tn + cih, Y
i
tn+cih)
Y i(s) = un(s) for s 6 tn Y i(tn + αh) = un(tn) +
i−1∑
j=1
aij(α)Kj for α ∈ (0, 1]
un+1(s) = un(s) for s 6 tn un+1(tn + αh) = un(tn) +
s∑
i=1
bi(α)Ki for α ∈ (0, 1]
where the Ki are said to be the stage variables. In the method, un is the numerical solution with step-size h
generated by the nth step of the method defined up to time tn for the delayed functional differential equation
u′(t) = G(t, ut) for t > t0, u(t) = φ(t) for t 6 t0,
where φ is said to be the starting data, t0 is the initial time, and ut is the continuous function ut(σ) = u(t+σ)
for σ ∈ [−τ, 0], where τ is the largest delay in the system (which is τ = τe + τm for our problem).
The fundamental difference between CRKs and FCRKs which enables the FCRK methods to remain explicit
is that the FCRKs are endowed with a continuous approximation Y i(t) associated with each stage, whereas
the CRK methods only have the single continuous approximation un+1(t) defined once the step is computed.
To implement this FCRK method for the system (12)–(13), the integrals need to be evaluated numerically
to sufficient accuracy to maintain the convergence order of the method. Although the composite trapezoidal
rule would be sufficient for second order accuracy we used fourth order composite methods, to allow for the
possible later implementation of a fourth order FCRK method. It is necessary to evaluate the integrals on
the same computational mesh as the underlying FCRK method. Since the numerical approximation Tn+1(t)
to T (t) is smooth on each interval [tn, tn+1], but not differentiable at the mesh points tn, the functions
ηm(Tn+1(t)) and ηm(Tn+1(t)) will also not be differentiable at the mesh points, and the convergence theory
of the composite quadrature methods will break down unless the mesh points tn of the FCRK method
are included as quadrature points for the integration. The exact solutions of delayed functional differential
equations also have discontinuous derivatives at breaking points as outlined in [4], which requires certain
time points to be included in the computational mesh. But because of the additional smoothing afforded by
the integrals in (12)–(13) the only breaking point that needs to be included in the mesh to obtain second
order convergence is the initial point t0.
Taking account of these considerations we used Simpson’s method to evaluate Me(tn+ cjh) using values of
me(tn+cjh, kh) andme(tn+cjh, (k+1/2)h), where cj = 0 or 1 for Heun’s method, and k ∈ {0, 1, ..., N}
is an integer with the step-size h of the FCRK method chosen so that τe = Nh. The necessary values of
me(t, a) were obtained from (13), evaluating the integrals in this formula using Milne’s method. To evaluate
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the nested integrals efficiently we store values of ηm(T (t)) and ηe(T (t)) at relevant points (tn + kh/4 for
k = 0, 1, 2, 3) and also store integrals which would otherwise be recomputed at multiple steps, including
ˆ tj
tj−τm
ηm(T (s)) da,
which appears in me(tj + kh, kh) and hence is required to evaluate Me(tj+k) for each of k = 0, 1, . . . , N .
The method is written to return a function handle that is created from the continuous approximation to the
solution generated by the method. This is returned to the user, which allows for the evaluation of P (t) and
T (t) at all points in the computational interval (not just at mesh points).
The explicit fourth order FCRK method proposed in [17] could be similarly implemented, but requires 6
stages to evaluate one step to fourth order, and so is not as advantageous as the 4-stage fourth order RK
method for ODEs, and would require the computation of some complicated integrals over 6 stages.
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